<DOC>
	<DOCNO>NCT02177448</DOCNO>
	<brief_summary>The efficacy safety Telmisartan capsule patient essential hypertension evaluate comparison Enalapril Maleate double blind trial .</brief_summary>
	<brief_title>BIBR 277 Capsule Patients With Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Enalapril</mesh_term>
	<mesh_term>Enalaprilat</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<criteria>Patient ≥ 25 year age Patient either male female Outpatient . Change inpatient allow study period Blood pressure measure 3 time 4week observation period ; last 2 measurement sit position ( intervals measurement must less 4 week ) stabilize systolic pressure ( within +/ 30 mmHg ) diastolic pressure within +/ 15 mmHg ) mean exceed 160 mmHg systolic 95 mmHG diastolic pressure Patient severe hypertension ( last 2 measurement observation period exceed 120 mmHg term diastolic blood pressure ) Patient secondary malignant hypertension Patient history severe cardiac failure , unstable angina , myocardial infarction within previous six month Patient atrioventricular conduction disturbance , atrial fibrillation severe arrhythmia Patient symptom cerebrovascular disorder Patient serious hepatic dysfunction ( either GOT ( glutamicoxaloacetic transaminase ) GPT ( glutamicpyruvic transaminase ) exceed 100 U ) Patient renal dysfunction ( serum creatinin ≥ 2.1 mg/dl ) Patient uncontrolled diabetic ( either follow test exceeds specify standard : fasting blood glucose exceed 151 mg/dl HbA1c exceed 8 % ) Patient history drug sensitivity ACE ( angiotensin convert enzyme ) inhibitor angiotensin II receptor antagonist Patient history angioedema due ACE inhibitor Patient hyperkalemia ( K exceed 5.5 mEq/l ) Patient receive enalapril start observation period Patient receive treatment investigational drug ( ) within three month start observation period Patients pregnant , breastfeeding , possible pregnant , want pregnant study period Patient condition investigator subinvestigator feel would inappropriate study participation</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>